Switch theme
Sign up to access all valuation multiples
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.
2020
758
Last FY Revenue $573M
Last FY EBITDA -$369M
$64.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, LakeShore Biopharma achieved revenue of $573M and an EBITDA of -$369M.
LakeShore Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See LakeShore Biopharma valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $573M | XXX | XXX | XXX |
| Gross Profit | XXX | $456M | XXX | XXX | XXX |
| Gross Margin | XXX | 79% | XXX | XXX | XXX |
| EBITDA | XXX | -$369M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -64% | XXX | XXX | XXX |
| EBIT | XXX | -$268M | XXX | XXX | XXX |
| EBIT Margin | XXX | -47% | XXX | XXX | XXX |
| Net Profit | XXX | -$433M | XXX | XXX | XXX |
| Net Margin | XXX | -76% | XXX | XXX | XXX |
| Net Debt | XXX | $171M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, LakeShore Biopharma's stock price is $1.
LakeShore Biopharma has current market cap of $20.4M, and EV of $64.7M.
See LakeShore Biopharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $64.7M | $20.4M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, LakeShore Biopharma has market cap of $20.4M and EV of $64.7M.
LakeShore Biopharma's trades at 0.1x EV/Revenue multiple, and -0.2x EV/EBITDA.
Equity research analysts estimate LakeShore Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
LakeShore Biopharma's P/E ratio is not available.
See valuation multiples for LakeShore Biopharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $20.4M | XXX | $20.4M | XXX | XXX | XXX |
| EV (current) | $64.7M | XXX | $64.7M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 0.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.2x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -0.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -0.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLakeShore Biopharma's revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $1.0M for the same period.
LakeShore Biopharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
LakeShore Biopharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for LakeShore Biopharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -49% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 49% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 53% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 126% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
LakeShore Biopharma acquired XXX companies to date.
Last acquisition by LakeShore Biopharma was XXXXXXXX, XXXXX XXXXX XXXXXX . LakeShore Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was LakeShore Biopharma founded? | LakeShore Biopharma was founded in 2020. |
| Where is LakeShore Biopharma headquartered? | LakeShore Biopharma is headquartered in United States of America. |
| How many employees does LakeShore Biopharma have? | As of today, LakeShore Biopharma has 758 employees. |
| Who is the CEO of LakeShore Biopharma? | LakeShore Biopharma's CEO is Mr. Xu Wang. |
| Is LakeShore Biopharma publicy listed? | Yes, LakeShore Biopharma is a public company listed on NAS. |
| What is the stock symbol of LakeShore Biopharma? | LakeShore Biopharma trades under LSB ticker. |
| When did LakeShore Biopharma go public? | LakeShore Biopharma went public in 2023. |
| Who are competitors of LakeShore Biopharma? | Similar companies to LakeShore Biopharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of LakeShore Biopharma? | LakeShore Biopharma's current market cap is $20.4M |
| Is LakeShore Biopharma profitable? | Yes, LakeShore Biopharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
